Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.52
- Piotroski Score 4.00
- Grade Buy
- Symbol (XFOR)
- Company X4 Pharmaceuticals, Inc.
- Price $0.53
- Changes Percentage (2.45%)
- Change $0.01
- Day Low $0.51
- Day High $0.54
- Year High $1.60
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $3.00
- High Stock Price Target $5.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.67
- Trailing P/E Ratio -1.51
- Forward P/E Ratio -1.51
- P/E Growth -1.51
- Net Income $-101,167,000
Income Statement
Quarterly
Annual
Latest News of XFOR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is There Now An Opportunity In Oxford Instruments plc (LON:OXIG)?
Oxford Instruments (LON:OXIG) experienced a 10% share price rise recently but remains below its yearly peak. Analysts suggest the stock is fairly priced, showing a 9.5% undervaluation....
By Yahoo! Finance | 1 day ago -
The week in classical: Wexford Festival Opera: Le convenienze ed inconvenienze teatrali; The Critic and more
The Wexford Festival Opera features a revival of Donizetti's comedy and Stanford's satire. The festival also showcases a witty new opera by Colm Tóibín, offering a mix of humor, drama, and musical e...
By The Guardian | 1 week ago -
Oxfordshire villagers oppose Russell Brand plan to use pub site for studios
In the village of Pishill, locals are divided over Russell Brand's plans to convert an 800-year-old pub into a studio. Residents fear losing their community asset and express concerns about Brand's in...
By The Guardian | 1 week ago
